PESAE03	Community preparedness to embrace new biomedical HIV prevention technologies. CHEDRA's experience with the Dapivirine vaginal ring and Female Sex Workers (FSWs) amidst a volatile atmosphere in Masaka, Uganda	Poster exhibition	Implementation science of scaling up prevention (including PrEP)
PESAE16	Impact of a community health worker intervention on PrEP knowledge and utilization in Rakai, Uganda: a mixed methods assessment	Poster exhibition	Implementation science of scaling up prevention (including PrEP)
EPF138	New opportunities in engagement: the expansion of Civil Society advisory groups by product developers	E-poster	Inclusion considerations for research and development and other trials
EPLBF07	Advancing HIV prevention research in pregnant and breastfeeding populations (PBFP): priority advocacy objectives and next steps	E-poster	Inclusion considerations for research and development and other trials
EPA021	HIV-1 subtype C Vif transmitted/founder (T/F) variants preferentially degrade APOBEC3G over APOBEC3F	E-poster	Innate immunity (including NK cells)
EPA022	Impact of chronic HIV infection on NK cell response through the HLA-E/NKG2x axis	E-poster	Innate immunity (including NK cells)
EPA023	Immunotherapeutic blockades targeting LAG-3 and PD-1 immune checkpoint inhibitors on invariant Natural Killer T cells: implications in chronic HIV infection	E-poster	Innate immunity (including NK cells)
EPA024	The effects of in utero HIV and anti-retroviral therapy exposure on infant T-cell and monocyte activation, function and regulation of immune-modulatory pathways	E-poster	Innate immunity (including NK cells)
EPA025	HLA-B*46 associates with rapid HIV disease progression in Asian cohorts and prominent differences in NK cell phenotypes	E-poster	Innate immunity (including NK cells)
EPA026	Characterizing the effect of intracellular storage pools of RANTES/CCL5 on HIV infection in macrophages	E-poster	Innate immunity (including NK cells)